Status:

TERMINATED

Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

Lead Sponsor:

Myrexis Inc.

Conditions:

Alzheimer Disease

Dementia

Eligibility:

All Genders

55+ years

Phase:

PHASE3

Brief Summary

This is a multinational, randomized, double blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of 800 mg twice daily MPC-7869 to placebo. Study subjects ...

Eligibility Criteria

Inclusion

  • Have had a diagnosis of probable Alzheimer's disease
  • Men or women ages greater than or equal to 55 years and living in the community at the time of enrollment (ie, not living in a rest home or nursing care facility).
  • Signed the subject Informed Consent Form (ICF) and is willing and able to participate for the duration of the study.
  • Ability to read and understand English, Dutch, Danish, Flemish, French, German, Italian, Spanish or Swedish to ensure compliance with cognitive testing and study visit procedures.
  • At least 6 years of education, or sufficient work history to exclude mental retardation.
  • Female subjects must be surgically sterile or postmenopausal for \> 1 year.
  • Adequate vision and hearing to participate in study assessments.
  • Subjects must have a reliable caregiver who can read, understand and speak same language.

Exclusion

  • Current evidence of other causes of dementia.. .
  • History of, or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate cancer may be enrolled at the discretion of the sponsor.
  • Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.
  • Major surgery and related complications not resolved within 12 weeks prior to Day 1.
  • Previous participation in an MPC-7869 clinical study.

Key Trial Info

Start Date :

May 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2008

Estimated Enrollment :

800 Patients enrolled

Trial Details

Trial ID

NCT00322036

Start Date

May 1 2006

End Date

December 1 2008

Last Update

August 5 2008

Active Locations (92)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 23 (92 locations)

1

Phoenix, Arizona, United States

2

Tucson, Arizona, United States

3

Costa Mesa, California, United States

4

San Diego, California, United States